Background
Methods
Study design and setting
Participants and variables
Statistical analysis
Results
Sociodemographic characteristics
Completed short-term survey | Completed long-term survey | |||||
---|---|---|---|---|---|---|
Baseline characteristics | ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA |
n | 487 | 1943 | 5715 | 462 | 1638 | 5004 |
Interval prime-boost (median (IQR) in days) | 84 (63–84) | 78 (63–84) | 42 (42–42) | 84 (63–84) | 65 (63–84) | 42 (42–42) |
Age (mean ± SD) | 55.87 ± 15.3 | 47.6 ± 13.89 | 45.87 ± 15.14 | 56.69 ± 15.61 | 45.1 ± 12.52 | 47.37 ± 15.23 |
Gender | ||||||
Male | 272 (55.9%) | 778 (40.0%) | 2428 (42.5%) | 257 (55.6%) | 448 (27.4%) | 2133 (42.6%) |
Female | 215 (44.1%) | 1165 (60.0%) | 3281 (57.4%) | 205 (44.4%) | 1189 (72.6%) | 2865 (57.3%) |
Diverse | 0 (0%) | 0 (0%) | 6 (0.1%) | 0 (0%) | 1 (0.1%) | 6 (0.1%) |
Residence | ||||||
Rural area1 | 181 (37.2%) | 597 (30.7%) | 1867 (32.7%) | 166 (35.9%) | 485 (29.6%) | 1676 (33.5%) |
Small town2 | 158 (32.4%) | 540 (27.8%) | 1700 (29.7%) | 147 (31.8%) | 414 (25.3%) | 1540 (30.8%) |
Medium-sized town3 | 60 (12.3%) | 236 (12.1%) | 694 (12.1%) | 59 (12.8%) | 193 (11.8%) | 607 (12.1%) |
City4 | 88 (18.1%) | 570 (29.3%) | 1454 (25.4%) | 90 (19.5%) | 546 (33.3%) | 1181 (23.6%) |
Employment | ||||||
Employed | 293 (60.2%) | 1458 (75.0%) | 3986 (69.7%) | 265 (57.4%) | 1347 (82.2%) | 3426 (68.5%) |
In education | 13 (2.7%) | 137 (7.1%) | 576 (10.1%) | 14 (3.0%) | 115 (7.0%) | 452 (9.0%) |
Unemployed | 9 (1.8%) | 37 (1.9%) | 147 (2.6%) | 8 (1.7%) | 22 (1.3%) | 134 (2.7%) |
Retired | 163 (33.5%) | 263 (13.5%) | 803 (14.1%) | 166 (35.9%) | 105 (6.4%) | 819 (16.4%) |
Other | 6 (1.2%) | 36 (1.9%) | 141 (2.5%) | 5 (1.1%) | 41 (2.5%) | 120 (2.4%) |
Not specified | 3 (0.6%) | 12 (0.6%) | 62 (1.1%) | 4 (0.9%) | 8 (0.5%) | 53 (1.1%) |
Education | ||||||
No degree | 0 (0%) | 0 (0%) | 8 (0.1%) | 0 (0%) | 0 (0%) | 8 (0.2%) |
Lower certificate | 24 (4.9%) | 52 (2.7%) | 212 (3.7%) | 23 (5.0%) | 39 (2.4%) | 202 (4.0%) |
Intermediate certificate | 88 (18.1%) | 217 (11.2%) | 695 (12.2%) | 82 (17.7%) | 184 (11.2%) | 658 (13.1%) |
Complete apprenticeship | 108 (22.2%) | 280 (14.4%) | 951 (16.6%) | 91 (19.7%) | 241 (14.7%) | 862 (17.2%) |
High school diploma | 71 (14.6%) | 373 (19.2%) | 1066 (18.7%) | 66 (14.3%) | 347 (21.2%) | 918 (18.3%) |
University degree | 186 (38.2%) | 994 (51.2%) | 2665 (46.6%) | 189 (40.9%) | 800 (48.8%) | 2249 (44.9%) |
Not specified | 10 (2.1%) | 27 (1.4%) | 118 (2.1%) | 11 (2.4%) | 27 (1.6%) | 107 (2.1%) |
Health status | ||||||
No pre-existing diseases | 148 (30.4%) | 764 (39.3%) | 2161 (37.8%) | 147 (31.8%) | 641 (39.1%) | 1792 (35.8%) |
Allergies | 119 (24.4%) | 556 (28.6%) | 1629 (28.5%) | 115 (24.9%) | 520 (31.7%) | 1453 (29%) |
Hypertension | 164 (33.7%) | 350 (18%) | 1008 (17.6%) | 140 (30.3%) | 250 (15.3%) | 976 (19.5%) |
Backpain | 83 (17.0%) | 269 (13.8%) | 831 (14.5%) | 84 (18.2%) | 250 (15.3%) | 754 (15.1%) |
Lung Disease | 40 (8.2%) | 110 (5.7%) | 411 (7.2%) | 37 (8.0%) | 113 (6.9%) | 387 (7.7%) |
Rheumatism/Autoimmune disease | 29 (6.0%) | 125 (6.4%) | 467 (8.2%) | 31 (6.7%) | 126 (7.7%) | 428 (8.6%) |
Depression | 24
(4.9%) | 90 (4.6%) | 413 (7.2%) | 25 (5.4%) | 86 (5.3%) | 359 (7.2%) |
Osteoarthritis | 43 (8.8%) | 125 (6.4%) | 324 (5.7%) | 42 (9.1%) | 97 (5.9%) | 311 (6.2%) |
Gastrointestinal disease | 26 (5.3%) | 104 (5.4%) | 375 (6.6%) | 26 (5.6%) | 89 (5.4%) | 341 (6.8%) |
Heart disease | 49 (10.1%) | 61 (3.1%) | 261 (4.6%) | 45 (9.7%) | 47 (2.9%) | 254 (5.1%) |
Diabetes | 37 (7.6%) | 70 (3.6%) | 208 (3.6%) | 32 (6.9%) | 60 (3.7%) | 204 (4.1%) |
Cancer | 25 (5.1%) | 38 (2.0%) | 127 (2.2%) | 27 (5.8%) | 43 (2.6%) | 130 (2.6%) |
Coagulation problems | 11 (2.3%) | 32 (1.6%) | 144 (2.5%) | 10 (2.2%) | 41 (2.5%) | 138 (2.8%) |
Kidney disease | 12 (2.5%) | 30 (1.5%) | 81 (1.4%) | 12 (2.6%) | 26 (1.6%) | 81 (1.6%) |
Liver disease | 6 (1.2%) | 17 (0.9%) | 73 (1.3%) | 7 (1.5%) | 17 (1.0%) | 69 (1.4%) |
Anaemia | 7 (1.4%) | 17 (0.9%) | 44 (0.8%) | 6 (1.3%) | 21 (1.3%) | 35 (0.7%) |
mSCQ-D (median (IQR))5 | 1 (0–2) | 0 (0–2) | 0 (0–2) | 1 (0–2) | 0 (0–2) | 1 (0–2) |
BMI (mean ± SD)6 | 27.0 ± 5.5 (NA7 = 7) | 25.8 ± 5.2 (NA = 22) | 26.1 ± 5.5 (NA = 64) | 26.8 ± 5.4 (NA = 7) | 25.8 ± 5.7 (NA = 17) | 26.2 ± 5.6 (NA = 63) |
Participants with other vaccination(s)8 | 30 (6.2%) | 135 (6.9%) | 456 (8.0%) | 23 (5.0%) | 97 (5.9%) | 389 (7.8%) |
Short-term survey
ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | |
---|---|---|---|
(n = 487) | (n = 1943) | (n = 5715) | |
Proportion of participants with at least one reported reaction | |||
Total | 282 (57.9%) | 1675 (86.2%) | 4338 (75.9%) |
< 1d interval vaccination – registration | 131 (57.7%) | 604 (84.2%) | 2430 (74.9%) |
1–5d interval vaccination – registration | 112 (57.4%) | 611 (86.1%) | 1387 (76.3%) |
> 5d interval vaccination – registration | 39 (60.9%) | 460 (89.1%) | 521 (79.7%) |
Perception | ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA |
---|---|---|---|
(n = 282, NA = 2) | (n = 1675) | (n = 4338, NA = 2) | |
1) Suspected association between reactions and vaccination | |||
Strongly disagree | 0 (0.0%) | 4 (0.2%) | 23 (0.5%) |
Disagree | 7 (2.5%) | 10 (0.6%) | 89 (2.1%) |
Agree | 62 (22.1%) | 194 (11.6%) | 768 (17.7%) |
Strongly agree | 211 (75.4%) | 1467 (87.6%) | 3456 (79.7%) |
2) Affection by the reactions | |||
Strongly disagree | 29 (10.4%) | 105 (6.3%) | 412 (9.5%) |
Disagree | 75 (26.8%) | 276 (16.5%) | 1110 (25.6%) |
Agree | 99 (35.4%) | 590 (35.2%) | 1501 (34.6%) |
Strongly agree | 77 (27.5%) | 704 (42.0%) | 1313 (30.3%) |
3) Long-term consequences by the reactions | |||
Strongly disagree | 233 (83.2%) | 1443 (86.1%) | 3661 (84.4%) |
Disagree | 41 (14.6%) | 193 (11.5%) | 553 (12.8%) |
Agree | 3 (1.1%) | 31 (1.9%) | 79 (1.8%) |
Strongly agree | 3 (1.1%) | 8 (0.5%) | 43 (1.0%) |
Long-term survey
ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | |
---|---|---|---|
(n = 462) | (n = 1638) | (n = 5004) | |
Medical consultation, thereof… | 69 (14.9%) | 287 (17.5%) | 796 (15.9%) |
Outpatient | |||
Yes | 61 (88.4%) | 248 (86.4%) | 667 (83.8%) |
Not yet, but planned | 6 (8.7%) | 36 (12.5%) | 117 (14.7%) |
No | 2 (2.9%) | 3 (1.0%) | 12 (1.5%) |
Inpatient/Clinic | |||
Yes | 13 (18.8%) | 21 (7.3%) | 85 (10.7%) |
Not yet, but planned | 1 (1.4%) | 2 (0.7%) | 9 (1.1%) |
No | 55 (79.7%) | 264 (92%) | 702 (88.2%) |
Pre-existing conditions | |||
Yes | 11 (15.9%) | 40 (13.9%) | 103 (12.9%) |
Partially | 22 (31.9%) | 95 (33.1%) | 291 (36.6%) |
No | 36 (52.2%) | 152 (53%) | 402 (50.5%) |
Suspected association to vaccination | |||
Yes | 3 (4.3%) | 16 (5.6%) | 36 (4.5%) |
Partially | 10 (14.5%) | 60 (20.9%) | 171 (21.5%) |
No | 56 (81.2%) | 211 (73.5%) | 589 (74.0%) |
Perceived affection by the health problems | |||
Strongly disagree | 6 (8.7%) | 24 (8.4%) | 72 (9%) |
Disagree | 7 (10.1%) | 38 (13.2%) | 88 (11.1%) |
Agree | 21 (30.4%) | 108 (37.6%) | 326 (41%) |
Strongly agree | 35 (50.7%) | 117 (40.8%) | 310 (38.9%) |
Perceived long-term consequences by the health problems | |||
Strongly disagree | 20 (29.0%) | 98 (34.1%) | 237 (29.8%) |
Disagree | 28 (40.6%) | 104 (36.2%) | 256 (32.2%) |
Agree | 15 (21.7%) | 54 (18.8%) | 212 (26.6%) |
Strongly agree | 6 (8.7%) | 31 (10.8%) | 91 (11.4%) |
ChAdOx1/ChAdOx1 | ChAdOx1/mRNA | mRNA/mRNA | |
---|---|---|---|
(n = 462) | (n = 1638) | (n = 5004) | |
Health problems leading to medical consultation, thereof… | |||
Musculoskeletal disorders | 35 (7.6%) | 123 (7.5%) | 321 (6.4%) |
Muscle weakness | 5 (1.1%) | 14 (0.9%) | 44 (0.9%) |
Back pain | 14 (3%) | 60 (3.7%) | 157 (3.1%) |
Pain in extremities | 15 (3.2%) | 57 (3.5%) | 150 (3.0%) |
Joint swelling | 5 (1.1%) | 19 (1.2%) | 42 (0.8%) |
Arthritis | 8 (1.7%) | 13 (0.8%) | 57 (1.1%) |
Subsultus | 0 (0%) | 14 (0.9%) | 33 (0.7%) |
Mobility disorder | 7 (1.5%) | 15 (0.9%) | 61 (1.2%) |
General symptoms | 25 (5.4%) | 108 (6.6%) | 357 (7.1%) |
Flu-like symptoms | 5 (1.1%) | 36 (2.2%) | 105 (2.1%) |
Dyspnoea | 4 (0.9%) | 10 (0.6%) | 55 (1.1%) |
Fever | 2 (0.4%) | 19 (1.2%) | 43 (0.9%) |
Nausea/vomiting | 2 (0.4%) | 18 (1.1%) | 71 (1.4%) |
Abdominal pain | 1 (0.2%) | 29 (1.8%) | 84 (1.7%) |
Fatigue | 13 (2.8%) | 51 (3.1%) | 174 (3.5%) |
Weakness | 14 (3.0%) | 52 (3.2%) | 156 (3.1%) |
Malaise | 11 (2.4%) | 45 (2.7%) | 122 (2.4%) |
Neurological disorders | 26 (5.6%) | 102 (6.2%) | 268 (5.4%) |
Headache | 12 (2.6%) | 60 (3.7%) | 160 (3.2%) |
Dizziness | 11 (2.4%) | 39 (2.4%) | 121 (2.4%) |
Paraesthesia | 8 (1.7%) | 28 (1.7%) | 63 (1.3%) |
Unconsciousness | 0 (0%) | 1 (0.1%) | 6 (0.1%) |
Neuralgia | 6 (1.3%) | 30 (1.8%) | 79 (1.6%) |
Seizure | 1 (0.2%) | 1 (0.1%) | 7 (0.1%) |
Minor stroke | 0 (0%) | 0 (0%) | 4 (0.1%) |
Paralysis | 0 (0%) | 2 (0.1%) | 4 (0.1%) |
Multiple sclerosis | 0 (0%) | 2 (0.1%) | 5 (0.1%) |
Cardiovascular disorders/Risk factors | 11 (2.4%) | 41 (2.5%) | 128 (2.6%) |
Diabetes | 5 (1.1%) | 4 (0.2%) | 19 (0.4%) |
Palpitations | 3 (0.6%) | 20 (1.2%) | 63 (1.3%) |
Chest pain | 2 (0.4%) | 16 (1.0%) | 53 (1.1%) |
Heart attack | 0 (0%) | 1 (0.1%) | 2 (0%) |
Myocarditis | 0 (0%) | 1 (0.1%) | 4 (0.1%) |
Vasculitis | 1 (0.2%) | 3 (0.2%) | 3 (0.1%) |
Pulmonary embolism | 0 (0%) | 0 (0%) | 1 (0%) |
Blood clot | 1 (0.2%) | 3 (0.2%) | 4 (0.1%) |
Coagulation disorder | 2 (0.4%) | 3 (0.2%) | 6 (0.1%) |
Unsolicited health problems | 38 (8.2%) | 162 (9.9%) | 389 (7.8%) |
Analysis by age and gender
Short-term survey
Long-term survey
Age < 55 years | Age ≥ 55 years | |||||
---|---|---|---|---|---|---|
ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | |
(n = 167) | (n = 1199) | (n = 3204) | (n = 295) | (n = 439) | (n = 1800) | |
Medical consultation, thereof... | 21 (12.6%) | 198 (16.5%) | 507 (15.8%) | 48 (16.3%) | 89 (20.3%) | 289 (16.1%) |
Outpatient | ||||||
Yes | 19 (90.5%) | 174 (87.9%) | 425 (83.8%) | 42 (87.5%) | 74 (83.1%) | 242 (83.7%) |
Planned | 2 (9.5%) | 24 (12.1%) | 76 (15.0%) | 4 (8.3%) | 12 (13.5%) | 41 (14.2%) |
No | 0 (0%) | 0 (0%) | 6 (1.2%) | 2 (4.2%) | 3 (3.4%) | 6 (2.1%) |
Inpatient/Clinic | ||||||
Yes | 3 (14.3%) | 13 (6.6%) | 49 (9.7%) | 10 (20.8%) | 8 (9.0%) | 36 (12.5%) |
Planned | 0 (0%) | 1 (0.5%) | 3 (0.6%) | 1 (2.1%) | 1 (1.1%) | 6 (2.1%) |
No | 18 (85.7%) | 184 (92.9%) | 455 (89.7%) | 37 (77.1%) | 80 (89.9%) | 247 (85.5%) |
Pre-existing conditions | ||||||
Yes | 2 (9.5%) | 30 (15.2%) | 61 (12%) | 9 (18.8%) | 10 (11.2%) | 42 (14.5%) |
Partially | 6 (28.6%) | 67 (33.8%) | 171 (33.7%) | 16 (33.3%) | 28 (31.5%) | 120 (41.5%) |
No | 13 (61.9%) | 101 (51.0%) | 275 (54.2%) | 23 (47.9%) | 51 (57.3%) | 127 (43.9%) |
Suspected association to vaccination | ||||||
Yes | 1 (4.8%) | 13 (6.6%) | 27 (5.3%) | 2 (4.2%) | 3 (3.4%) | 9 (3.1%) |
Partially | 5 (23.8%) | 43 (21.7%) | 116 (22.9%) | 5 (10.4%) | 17 (19.1%) | 55 (19%) |
No | 15 (71.4%) | 142 (71.7%) | 364 (71.8%) | 41 (85.4%) | 69 (77.5%) | 225 (77.9%) |
Female | Male | |||||
---|---|---|---|---|---|---|
ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | |
(n = 205) | (n = 1189) | (n = 2865) | (n = 257) | (n = 448) | (n = 2133) | |
Medical consultation, thereof... | 33 (16.1%) | 233 (19.6%) | 533 (18.6%) | 36 (14%) | 53 (11.8%) | 261 (12.2%) |
Outpatient | ||||||
Yes | 32 (97.0%) | 205 (88.0%) | 453 (85.0%) | 29 (80.6%) | 42 (79.2%) | 213 (81.6%) |
Planned | 1 (3.0%) | 27 (11.6%) | 75 (14.1%) | 5 (13.9%) | 9 (17.0%) | 41 (15.7%) |
No | 0 (0%) | 1 (0.4%) | 5 (0.9%) | 2 (5.6%) | 2 (3.8%) | 7 (2.7%) |
Inpatient/Clinic | ||||||
Yes | 5 (15.2%) | 16 (6.9%) | 44 (8.3%) | 8 (22.2%) | 5 (9.4%) | 41 (15.7%) |
Planned | 0 (0%) | 2 (0.9%) | 5 (0.9%) | 1 (2.8%) | 0 (0%) | 4 (1.5%) |
No | 28 (84.8%) | 215 (92.3%) | 484 (90.8%) | 27 (75.0%) | 48 (90.6%) | 216 (82.8%) |
Pre-existing conditions | ||||||
Yes | 2 (6.1%) | 28 (12.0%) | 60 (11.3%) | 9 (25.0%) | 12 (22.6%) | 43 (16.5%) |
Partially | 10 (30.3%) | 85
(36.5%) | 217 (40.7%) | 12 (33.3%) | 10 (18.9%) | 73 (28.0%) |
No | 21 (63.6%) | 120 (51.5%) | 256 (48%) | 15 (41.7%) | 31 (58.5%) | 145 (55.6%) |
Suspected association to vaccination | ||||||
Yes | 1 (3%) | 16 (6.9%) | 26 (4.9%) | 2 (5.6%) | 0 (0%) | 10 (3.8%) |
Partially | 4 (12.1%) | 49 (21%) | 118 (22.1%) | 6 (16.7%) | 11 (20.8%) | 53 (20.3%) |
No | 28 (84.8%) | 168 (72.1%) | 389 (73%) | 28 (77.8%) | 42 (79.2%) | 198 (75.9%) |